Monographie - Tigecycline - Stabilis 4.0

Ultimele actualizari :
19/11/2024

Antibiotic

Tigecycline

Injectabil

Stabilitatea in solutie

Stabilitatea in amestec

Factorii care influenteaza stabilitatea

Compatibilitate

Microunde

Bibliografie

pdf

Formula chimica

Denumirea comerciala

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eticina	Mexic
Grexyl	Mexic
Linicetil	Mexic
Mrsacin	Turcia
Tecygen	Chilli
Tigecid	Turcia
Tigecilina	Argentina, Chilli, Ecuador
Tigecycline	Canada
Tigetop	Chilli
Tizoxim	Argentina
Tygacil	Arabia Saudita, Argentina, Austria, Belgia, Canada, Chilli, Columbia, Danemarca, Ecuador, Elvetia, Emiratele Arabe Unite, Finlanda, Franta, Germania, Grecia, Irlanda, Islanda, Italia, Japonia, Luxemburg, Malaezia, Marea Britanie, Mexic, Norvegia, noua Zeelandă, Olanda, Peru, Polonia, Portugalia, Romania, Spania, SUA, Suedia, Turcia, Ungaria, Venezuela
Zomiprerin	Peru

Bibliografie

Injectabil

Bibliografie : Tigecycline

	tip	publicare
2262	ziar	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laborator	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	ziar	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laborator	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laborator	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laborator	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laborator	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	ziar	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	ziar	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	ziar	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	ziar	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	ziar	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales